Explore BrainChild Bio careers and hiring status. Find jobs at BrainChild Bio and official application links when roles are open. Funding stage: Series A. Headcount: 11-50. BrainChild Bio is a Seattle-based clinical-stage biotech spun out of Seattle Children's, developing CAR T cell therapies for pediatric brain and CNS tumors. Its lead program targets diffuse intrinsic pontine glioma (DIPG), building on research from Dr. Michael Jensen's lab, and it closed a $116M Series A to fund a pivotal Phase 2 trial.
This page summarizes open roles, company profile signals, and official application paths so candidates can quickly evaluate fit before applying. Use the role list below to identify team focus, review location patterns, and jump to source listings. For broader comparison across the market, continue to the full company directory and jobs explorer.
BrainChild Bio is a Series A stage AI startup, founded in 2023, with $116M in total disclosed funding. Its most recent round was a $116M Series A in Sep 2026. It has no open roles listed at the moment; new BrainChild Bio openings are tracked daily. Source: Fast AI Jobs company dataset, updated Sep 2026.
Company profile last updated on Sep 12, 2026.
BrainChild Bio careers and hiring status: no open roles are currently listed here, but you can review the company profile and check the official career page for the latest openings. Official careers page
BrainChild Bio is an biotech company. BrainChild Bio is a Seattle-based clinical-stage biotech spun out of Seattle Children's, developing CAR T cell therapies for pediatric brain and CNS tumors. Its lead program targets diffuse intrinsic pontine glioma (DIPG), building on research from Dr. Michael Jensen's lab, and it closed a $116M Series A to fund a pivotal Phase 2 trial.
Open positions
Check the official career page, browse adjacent companies, or subscribe for new openings.
Candidate questions
BrainChild Bio is a Seattle-based clinical-stage biotech spun out of Seattle Children's, developing CAR T cell therapies for pediatric brain and CNS tumors. Its lead program targets diffuse intrinsic pontine glioma (DIPG), building on research from Dr. Michael Jensen's lab, and it closed a $116M Series A to fund a pivotal Phase 2 trial.
BrainChild Bio does not have open roles listed on our platform right now. Visit the official company website or career page for the latest openings, or subscribe to get notified when new roles are posted.
BrainChild Bio has raised $116M in total. The latest known stage is Series A.
BrainChild Bio reports an employee count of 11-50.
BrainChild Bio was founded in 2023.
BrainChild Bio is associated with Biotech, Healthcare.
Company context
BrainChild Bio is a Series A stage AI startup, founded in 2023, with $116M in total disclosed funding. Its most recent round was a $116M Series A in Sep 2026. It has no open roles listed at the moment; new BrainChild Bio openings are tracked daily. Source: Fast AI Jobs company dataset, updated Sep 2026.